Clonidine-Phenylephrine-Strattera Interaction Guidelines

Introduction to Interaction Risks

The American Academy of Child and Adolescent Psychiatry recommends baseline cardiovascular assessment before initiating clonidine, including detailed personal and family cardiac history, baseline heart rate and blood pressure, with ECG consideration if cardiac risk factors exist 1

The American Academy of Child and Adolescent Psychiatry suggests starting clonidine at the absolute minimum dose of 0.05 mg at bedtime, with slow titration not exceeding 0.3 mg/day 1
The American Journal of Obstetrics and Gynecology recommends titration of clonidine by 0.1 mg BID-TID intervals to maximum 0.4 mg daily, but lower maximums are safer with concurrent atomoxetine 2
Atomoxetine should be started at 40 mg daily and adjusted only every 7-14 days when combined with clonidine, with a maximum dosing of 1.4 mg/kg/day or 100 mg/day 1, 3

Clonidine can cause bradycardia, hypotension, and AV conduction abnormalities, with documented cases of complete AV block when combined with other cardiac-active medications 1
Exercise extreme caution in patients with AV conduction disease, as clonidine combined with other cardiac-active medications significantly increases risk of complete heart block 1
Baseline and periodic heart rate and blood pressure measurements are necessary, along with ECG monitoring if any cardiac risk factors are present 1

Pediatric patients represent the most common population using clonidine-atomoxetine combinations for ADHD management, requiring careful consideration of enhanced phenylephrine response and potential for rebound hypertension 1
Patients with hepatic insufficiency require lower doses of atomoxetine and more frequent monitoring 1